KALV Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 2.3%, SMA50 1.51%, SMA200 15.02%). The stock’s 14-day RSI is 53.73 (neutral), while the ATR of 0.8 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -17.05% below its high and over 70.66% above its low.

KalVista Pharmaceuticals, Inc. has 49.95 million shares outstanding. The public float is 27.73 million shares, elevated short interest at 22.71% of float. This equals 10.06 million shares. The short ratio is 5.68 days. Institutional investors hold 139.27% of the float. Insiders own 1.72%. Venrock Healthcare Capital Partners III, L.P. holds 5.09 million shares, Palleiko Benjamin L has 479.99 thousand shares and Yea Christopher has 229.92 thousand shares. Over the past six months, insider transactions show net selling. They sold 123.54 thousand shares across 29 transactions.

The stock is currently trading near its 52-week high $9.83 and $27.00. With a market capitalization of about $1.44 billion, KalVista Pharmaceuticals, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~-0.29). Key stats such as the average daily volume over the past year has been around 3.63 million shares, in line with its 52-week average. Headquartered in Framingham, MA, KalVista Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Benjamin L. Palleiko, the company employs approximately 275 people and listed since April 09, 2015. KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need.

KalVista Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $21.88. This means the shares are trading above this model’s fair value.

KalVista Pharmaceuticals, Inc. generated EPS of -$4.00 over the past year. Five-year average earnings growth is -17.63%. The latest quarter delivered EPS of -$0.92. The next quarter is forecast at $nan. Next year's EPS is expected at $12.21. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 7 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $42.00 to $27.00. The high target offers 55.56% upside. The low target suggests 0.0% downside. The mean target is $31.73. This offers 17.52% upside. KalVista Pharmaceuticals, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 15, 2026, missed forecasts by 144.52%. The prior quarter beat by 144.52%. Over the last six quarters, Apple has recorded several small beats. These include 8.24% in November 10, 2025.

KalVista Pharmaceuticals, Inc. trades at a P/E ratio of -8.36, slightly below the S&P 500 average, with a price-to-sales ratio of 12.4 and a price-to-book ratio of -503.31 indicating negative book value, which may reflect financial stress. The P/FCF stands at -25.42, also below market averages.

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) shares are flat -5.2% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows KalVista Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -8.36. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $26.59, suggesting -1.52% downside. Our AI forecast model points to short-term strength (4.3% over two weeks), a medium-term rise (124.0% over three months), and a longer-term gain (7.67% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that KalVista Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4.3%, with price expected at $28.16 by June 24, 2026, within a range of $26.40 to $30.02 3-Month Outlook: Projected rise of 124.0%, reaching $60.48 by September 08, 2026, with a range of $59.59 to $62.00. 1-Year Outlook: Projected gain of 7.67%, with price at $29.07 by June 10, 2027, within a range of $28.03 to $30.07.